Table 1

Demographic and baseline clinical characteristics of the Parkinson’s disease patients at study entry

VariablesPlacebo (n=20)Steroid (n=20)p value*
Results expressed as mean ± SD.
*Umpired t test; †χ2 analyses.
Age, years72.4±3.973.6±4.30.34
Gender, M/F11/910/10NS†
Duration of illness, years8.1±1.88.2±2.10.81
Antiparkinsonian drugs
Levodopa/caridpopa or levodopa/benserazide2019
    Amantadine89
    Bromocriptine1213
    Trihexyphenidyl670.98†
Reason for discontinuing antiparkinsonian drugs
    Psychiatric symptoms65
    Dyskinesia78
    On-off34
    Diarrhoea22
    None210.96†
Heart rate (beats/min)127±13128±150.74
Systolic blood pressure (mm Hg)93±991±140.61
Diastolic blood pressure (mm Hg)54±756±120.60
Body temperature (°C)39.8±0.739.6±0.70.37
Serum creatine kinase (IU)4904±24064143±22040.31
White blood cell count (per mm3)17392±478916210±48250.44